Effectiveness of two antifolate prophylactic strategies against malaria in HIV-positive pregnant women in Bangui, Central African Republic: study protocol for a randomized controlled trial (MACOMBA)

Trials

Muriel Vray⁶  Mirdad Kazanji¹  Lenaig Le-Fouler⁶  Olga Sakanga¹  Jean Methode Moyen²  Aude Boulay¹  Sandrine Moussa¹  Ghislain Géraud Banthas Bata³  Samuel Gondje⁴  Eugène Serdouma⁵  Abdoulaye Sepou⁷  Alexandre Manirakiza¹ 

[1] Institut Pasteur of Bangui, International Network of Instituts Pasteur, PO Box 923, Pasteur Avenue, Bangui, Central African Republic;Malaria Programme Division, Ministry of Public Health, Population and AIDS Control, PO Box 883, Bangui, Central African Republic;Maternité du Centre de Santé des Castors, Ministry of Public Health, Population and AIDS Control, PO Box 1383, Bangui, Central African Republic;Maternité de la Gendarmerie, Ministry of Public Health, Population and AIDS Control, PO Box 1383, Bangui, Central African Republic;Hôpital de l’Amitié, Ministry of Public Health, Population and AIDS Control, PO Box 1383, Bangui, Central African Republic;Institut Pasteur of Paris, Unité d'Epidémiologie des Maladies Emergentes, 25 Rue du Dr Roux, 75724 Paris CEDEX 15, France;Hôpital Communautaire of Bangui, Ministry of Public Health, Population and AIDS Control, PO Box 1383, Bangui, Central African Republic

关键词: Antifolate;    Pregnancy;    HIV;    Malaria prevention;   

Others  :  1093235
DOI  :  10.1186/1745-6215-14-255

 received in 2013-01-30, accepted in 2013-08-05,  发布年份 2013

【 摘 要 】

Background

Co-infection with malaria parasite and HIV is an emerging public health problem in tropical areas, particularly in pregnant women, and management of the concurrent effects of these two infections is challenging. Co-trimoxazole is a sulfamide preparation used to prevent opportunistic infections in HIV-infected patients, and many studies have reported that it has significant activity against malaria. As the efficacy of intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) against malaria is decreasing, co-trimoxazole might be an alternative for preventing malaria among HIV-infected populations. The aim of this study is to compare the effectiveness of SP-IPT, which is recommended for the prevention of malaria during pregnancy in the Central African Republic, with that of a daily dose of co-trimoxazole against P. falciparum infections among HIV-infected pregnant women in Bangui, the capital of the Central African Republic.

Methods/Design

The MACOMBA study (MAternity and COntrol of Malaria-HIV co-infection in BAngui) is a multicentre open-label randomized clinical trial conducted at four maternity hospitals in Bangui. All HIV-infected pregnant women presenting for an antenatal clinic visit between the weeks 16 and 28 of amenorrhoea, with a CD4 count of more than 350 cells/mm³, will be eligible. All the women will provide written consent before being enrolled in the study and will then be randomly allocated to either SP-IPT (25 mg of sulfadoxine and 1.25 mg of pyrimethamine) or daily co-trimoxazole doses (960 mg per dose). The primary end-point is the placental malaria parasitaemia rate at delivery. Other main outcome measures include the number of malaria episodes during pregnancy, safety, and treatment compliance. Furthermore, the frequency of molecular resistance markers dhfr and dhps will be measured.

Discussion

In this trial, we seek to confirm whether co-trimoxazole is operationally suitable to replace SP-IPT in order to prevent malaria among pregnant women infected with HIV in the Central African Republic.

Trial registration

ClinicalTrials.gov Identifier: NCT01746199.

【 授权许可】

   
2013 Manirakiza et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Joint United Nations Programme on HIV/AIDS: Report on the global AIDS epidemic. Geneva; 2008.
• [2]Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
• [3]Butcher GA: HIV and malaria: a lesson in immunology? Parasitol Today 1992, 8:307-311.
• [4]Martin-Blondel G, Soumah M, Camara B, Chabrol A, Porte L, Delobel P, Cuzin L, Berry A, Massip P, Marchou B: [Impact of malaria on HIV infection]. Med Mal Infect 2010, 40:256-267.
• [5]Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, Omoding N, Okongo M, Malamba S, Ojwiya A: Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000, 356:1051-1056.
• [6]ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, Rogerson SJ, Steketee RW: The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004, Suppl 2:41-54.
• [7]Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, Breman JG: Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996, Suppl 1:42-49.
• [8]WHO/AFRO: A strategic framework for malaria prevention and control during pregnancy in the African region. Brazaville; 2004. Accessed on 20 July 2010 at [http://whqlibdocwhoint/afro/2004/AFR_MAL_0401pdf webcite]
• [9]Steketee RW, Wirima JJ, Slutsker L, Breman JG, Heymann DL: Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Am J Trop Med Hyg 1996, Suppl 1:17-23.
• [10]Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel M: Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis 2006, 194:286-293.
• [11]Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P, Lule J, Coutinho A, Solberg P: Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006, 367:1256-1261.
• [12]Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, Kone A, Guindo A, Dicko A, Beavogui AH, Djimde AA, Lyke KE, Diallo DA, Doumbo OK, Plowe CV: Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005, 192:1823-1829.
• [13]Bloland PB, Redd SC, Kazembe P, Tembenu R, Wirima JJ, Campbell CC: Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet 1991, 337:518-520.
• [14]Hamel MJ, Holtz T, Mkandala C, Kaimila N, Chizani N, Bloland P, Kublin J, Kazembe P, Steketee R: Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. Am J Trop Med Hyg 2005, 73:609-615.
• [15]Khalil IF, Ronn AM, Alifrangis M, Gabar HA, Jelinek T, Satti GM, Bygbjerg IC: Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolatereductase and dihydropteroate synthase genotypes. Am J Trop Med Hyg 2005, 73:174-177.
• [16]Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Bamgboye AE, Babalola CP, Happi TC, Gbotosho GO: Effects of antifolates–co-trimoxazole and pyrimethamine-sulfadoxine–on gametocytes in children with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz 2005, 100:451-455.
• [17]Forna F, McConnell M, Kitabire FN, Homsy J, Brooks JT, Mermin J, Weidle PJ: Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS reviews 2006, 8:24-36.
• [18]Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC: High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996, 90:179-181.
• [19]Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, Sharp B: Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003, 361:1174-1181.
• [20]Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A: Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria. Am J Trop Med Hyg 2005, 72:581-585.
• [21]Menard D, Djalle D, Manirakiza A, Yapou F, Siadoua V, Sana S, Matsika-Claquin MD, Nestor M, Talarmin A: Drug-resistant malaria in Bangui, Central African Republic: an in vitro assessment. Am J Trop Med Hyg 2005, 73:239-243.
• [22]Menard D, Djalle D, Yapou F, Manirakiza A, Talarmin A: Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Bangui, Central African Republic. Am J Trop Med Hyg 2006, 74:205-210.
• [23]Menard D, Yapou F, Manirakiza A, Djalle D, Matsika-Claquin MD, Talarmin A: Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am J Trop Med Hyg 2006, 75:381-387.
• [24]Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe1 CV: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002, 185:380-388.
• [25]Schleiermacher D, Rogier C, Spiegel A, Tall A, Trape JF, Mercereau-Puijalon O: Increased multiplicity of Plasmodium falciparum infections and skewed distribution of individual msp1 and msp2 alleles during pregnancy in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Am J Trop Med Hyg 2001, 64:303-309.
• [26]Van Geertruyden JP, Menten J, Colebunders R, Korenromp E, D'Alessandro U: The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 2008, 7:134. BioMed Central Full Text
• [27]Newman PM, Wanzira H, Tumwine G, Arinaitwe E, Waldman S, Achan J, Havlir D, Rosenthal PJ, Dorsey G, Clark TD, Deborah C: Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J 2009, 8:254. BioMed Central Full Text
• [28]Malamba SS, Mermin J, Reingold A, Lule JR, Downing R, Ransom R, Kigozi A, Hunt BM, Hubbard A, Rosenthal PJ, Dorsey G: Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 2006, 75:375-380.
• [29]Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC: Dihydrofolatereductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg 2003, 68:586-589.
• [30]Manirakiza A, Serdouma E, Heredeibona LS, Djalle D, Madji N, Moyen M, Soula G, Le Faou A, Delmont J: Rational case management of malaria with a rapid diagnostic test, Paracheck Pf(R), in antenatal health care in Bangui. Central African Republic. BMC Publ Health 2012, 12:482. BioMed Central Full Text
• [31]Ministère de la santé Publique, de la Population et de la Lutte contre le VIH/SIDA (République Centrafricaine): Politique nationale de la lutte contre le Paludisme. 2008.
• [32]World Health Organization: Rapid Advice: use of antiretroviral drugs for treating pregnant women and preventing HIV Infection in infants. Geneva: WHO Press; 2009. Accessed 9 February 2010 at [http://www.who.int/hiv/pub/mtct/rapid_advice_mtct.pdf webcite]
• [33]Ministère de la santé Publique, de la Population et de la Lutte contre le VIH/SIDA (République Centrafricaine): Prise en charge intégrée de la grossesse et de l’accouchementdans le contexte de la prévention de la transmission parents/enfants du VIH (PCIGA/PTPE). 2011.
• [34]Joint United Nations Programme on HIV/AIDS: Guide du conseil du dépistage du VIH à l’initiative du soignant dans les établissements de santé. Geneva; 2007. Accessed 9 February 2010 at [http://whqlibdoc.who.int/publications/2007/9789242595567_fre.pdf webcite]
• [35]Snounou G, Singh B: Nested polymerase chain reaction analysis of Plasmodium Parasites. In Molecular Medicine, Malaria Methods and Protocols. Edited by Doolan D. Totowa, NJ: Humana Press; 2002:189-203.
• [36]World Health Organization: Report on the global AIDS epidemic. Geneva; 2008. WHO Library Cataloguing in-publication Data. UNAIDS/08.25E/JC1510E ISBN 978 92 9 1737116. Accessed 9 February 2010 at [http://whqlibdoc.who.int/unaids/2008/9789291737116_eng.pdf webcite]
• [37]Kattenberg JH, Tahita CM, Versteeg IA, Tinto H, TraoreCoulibaly M, D'Alessandro U, Schallig HD, Mens PF: Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in Nanoro, Burkina Faso. Am J Trop Med Hyg 2012, 87:251-256.
• [38]Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE: Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolatereductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995, 52:565-568.
• [39]Dorton BJ, Mulindwa J, Li MS, Chintu NT, Chibwesha CJ, Mbewe F, Frenkel LM, Stringer JS, Chi BH: CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention. BJOG 2011, 118:495-499.
• [40]Le Port A, Cottrell G, Echavanne C, Briand V, Bouraima A, Guerra J, Choudat I, Massougbodji A, Fayomi B, Migot-Nabias F, Garcia A, Cot M: Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin. Am J Trop Med Hyg 2011, 84:270-275.
• [41]PACOME Research Team: Prevention of pregnancy-associated malaria in HIV-infected women: cotrimoxazole prophylaxis versus mefloquine (PACOME). ClinicalTrialsgov Identifier: NCT00970879. Accessed 24 December 2012 at [http://www.clinicaltrials.gov/ct2/show/NCT00970879?term=NCT00970879&rank=1 webcite]
• [42]MiPPAD Research Team: Evaluation of alternative antimalarial drugs for malaria in pregnancy (MiPPAD). ClinicalTrialsgov Identifier: NCT00811421. Accessed 24 December 2012 at [http://www.clinicaltrials.gov/ct2/show/NCT00811421?term=NCT00811421&rank=1 webcite]